Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NMTC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNeuroOne regains Nasdaq compliance after stock price recovers above $1.00
Filed May 4, 2026 · Period ending April 30, 2026 · ~1 min read
Key Changes
-
medium
Nasdaq confirmed NeuroOne's stock bid price stayed at or above $1.00 for 10 consecutive business days, closing a deficiency notice from May 2025. The company remains listed on Nasdaq Capital Market.
Item 3.01 view on EDGAR →
Summary
NeuroOne Medical Technologies received formal notification from Nasdaq on April 30, 2026, that it has regained compliance with the exchange's minimum bid price requirement. The company's stock closed at or above $1.00 per share for 10 consecutive business days, resolving a deficiency notice issued in May 2025 when the stock had traded below that threshold for 30 straight days. The matter is now closed.
For retail investors, this removes the immediate threat of delisting from the Nasdaq Capital Market, which would have forced the stock to trade on less liquid over-the-counter markets. While regaining compliance is positive, the stock's recent history near the $1.00 minimum suggests ongoing volatility. Investors should monitor whether the stock price can sustain levels well above $1.00 and watch for any fundamental business developments that might support a more durable recovery.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 30, 2026, the Company received a letter from the Staff notifying the Company that it had regained compliance with the Bid Price Rule as a result of the closing bid price of the Company’s common stock being at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, the letter indicated the Company is in compliance with the Bid Price Rule and the matter is closed.
NeuroOne received formal notification from Nasdaq that it has regained compliance with the minimum $1.00 bid price requirement after its stock closed at or above $1.00 for 10 consecutive business days. This resolves a deficiency notice the company received in May 2025 when its stock had traded below $1.00 for 30 consecutive days. The matter is now closed and the company remains listed on the Nasdaq Capital Market.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify